Clinical Data Transparency Would Counter-Balance Off-Label Promotion – NEJM
This article was originally published in The Pink Sheet Daily
Executive Summary
Giving independent researchers access to patient-level data and requiring public release of clinical study reports would help to offset the weakening of FDA’s oversight caused by industry’s First Amendment victories, a Boston University professor says.